The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

1. (Currently amended) A bisacyloxypropylcysteine conjugate according to formula (1),



(1)

where

R_1 and R_2 can be identical or different and are ~~C_8-C_{22} alkyl, alkenyl or alkynyl~~ fatty acid radicals which are bonded by way of the carboxyl group;

Y = -NH-, -O- , -S-, or -OCO-;

R_3 is a ~~covalently, ionically or associatively bonded conjugate radical, in particular a water-soluble and physiologically tolerated, covalently or ionically bonded polymer, in particular~~ covalently bonded polyethylene glycol (polyoxyethylene) $-(CH_2-CH_2-O)_m-CH_2-CH_2-X$,

where X = OR, N[R]$_2$, SR or COOR, and

R = H, benzyl-, or C_{1-6} alkyl, where ~~several radicals R~~ , when X = N[R]$_2$, the [R] groups can be identical or different~~, a polyoxyethylene-polyoxypropylene copolymer, a dextran, a sugar, a polyvinylpyrrolidone, an alginate, a pectin or a collagen, and where the polymeric radical R_3 is substituted once, twice, or several times by~~

~~  ~~

.

2. (Currently amended) ~~A~~ The bisacyloxypropylcysteine conjugate ~~as claimed in~~ of claim 1, ~~characterized in that the radicals $R_{1,2}$, which can be identical or different, are $C_{7,25}$, preferably $C_{9,22}$ alkyl, -alkenyl or -alkynyl groups, and~~ wherein the unsaturated positions are preferably in the cis configuration, with the C_8-C_{22} alkyl, alkenyl and alkynyl fatty acid radicals ~~being~~ are branched or unbranched, cyclic or cycloalkyl-substituted radicals.

3. (Currently Amended) ~~A~~ The bisacyloxypropylcysteine conjugate ~~as claimed in~~ of claim 1, ~~characterized in that the~~ wherein a molecular weight of ~~a water-soluble polymer radical is selected such that it amounts to~~ the covalently bonded polyethylene glycol (polyoxyethylene) -$(CH_2$-CH_2-$O)_n$-CH_2-CH_2-X is from 100 to 30 000 daltons ~~per conjugate molecule~~.

4. (Currently Amended) ~~A~~ The bisacyloxypropylcysteine conjugate ~~as claimed in~~ of claim 1, ~~characterized in that the polyethylene glycol of the radical R_3 has a chain length~~ wherein m ~~of~~ is from 5 to 700~~, preferably of from 100 to 500~~.

5. (Currently Amended) ~~A~~ The bisacyloxypropylcysteine conjugate ~~as claimed in~~ of claim 1, ~~characterized in that~~ wherein the ~~compound~~ bisacyloxypropylcysteine conjugate is a S-[2,3-bis(acyloxy)-(2S)-propyl]-L-cysteinylcarboxypolyethylene glycol~~, preferably S-[2,3-bis(palmitoyloxy)-(2s)-propyl]-L-cysteinylcarboxypolyethylene glycol~~.

6. (Currently Amended) ~~A~~ The bisacyloxypropylcysteine conjugate ~~as claimed in~~ of claim 1, characterized in that the compound is a S-[2,3-*bis*(acyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol~~, preferably S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol~~.

7. (Currently Amended) A pharmaceutical composition, comprising a bisacyloxypropylcysteine conjugate ~~as claimed in claim~~ according to formula (1),



(1)

where

R_1 and R_2 can be identical or different and are C_8-C_{22} alkyl, alkenyl or alkynyl fatty acid radicals which are bonded by way of the carboxyl group;

Y = -NH-, -O- , -S-, or -OCO-;

R_3 is a covalently bonded polyethylene glycol (polyoxyethylene) $-(CH_2-CH_2-O)_m-CH_2-CH_2-X$,

where X = OR, $N[R]_2$, SR or COOR, and

[R] = H, benzyl-, or C_1-$_6$ alkyl, where , when X = $N[R]_2$, the [R] groups can be identical or different.

8. (Currently Amended) The pharmaceutical composition ~~as claimed in~~ of claim 7, ~~characterized in that it comprises pharmaceutical additives or auxiliary substances and, preferably,~~ further comprising a pharmaceutically tolerated excipient.

9. (Currently Amended) The pharmaceutical composition ~~as claimed in~~ of claim 7, wherein the pharmaceutical composition is in the form of a formulation which is suitable for injection, for inhalation or for intranasal or topical administration.

10. (Cancel)

11. (New) The bisacyloxypropylcysteine conjugate of claim 4, wherein m is from 100 to 500.

12. (New) The bisacyloxypropylcysteine conjugate of claim 5, wherein the bisacyloxypropylcysteine conjugate is S-[2,3-bis(palmitoyloxy)-(2S)-propyl]-L-cysteinylcarboxypolyethylene glycol.

13. (New) The bisacyloxypropylcysteine conjugate of claim 6, wherein the bisacyloxypropylcysteine conjugate is S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol.

14. (New) A method of stimulating an immune response to an antigen in an animal or human, comprising the step of

simultaneously administering to the animal or human

the antigen; and

a bisacyloxypropylcysteine conjugate according to formula (1),



(1)

where

R_1 and R_2 can be identical or different and are C_8-C_{22} alkyl, alkenyl or alkynyl fatty acid radicals which are bonded by way of the carboxyl group;

Y = -NH-, -O- , -S-, or -OCO-;

R_3 is a covalently bonded polyethylene glycol (polyoxyethylene) $-(CH_2-CH_2-O)_m-CH_2-CH_2-X$,

where X = OR, $N[R]_2$, SR or COOR, and

R = H, benzyl-, or C_{1-6} alkyl, where, when X = $N[R]_2$, the [R] groups can be identical or different.

15. (New) A bisacyloxypropylcysteine conjugate according to formula (1),



(1)

where

R_1 and R_2 can be identical or different and are C_8-C_{22} alkyl, alkenyl or alkynyl fatty acid radicals which are bonded by way of the carboxyl group;

Y = -NH-, -O- , -S-, or -OCO-;

R_3 is a covalently bonded polyethylene glycol (polyoxyethylene) -$(CH_2$-CH_2-$O)_n$-CH_2-CH_2-X,

where X = OR, $N[R]_2$, SR or COOR, and

R = H, benzyl-, or C_1-$_6$ alkyl, where, when X = $N[R]_2$, the [R] groups can be identical or different,

and wherein said bisacyloxypropylcysteine conjugate is a S-[2,3-bis(acyloxy)-(2S)-propyl]-L-cysteinylcarboxypolyethylene glycol.

16. (New) A bisacyloxypropylcysteine conjugate according to formula (1),



(1)

where

R_1 and R_2 can be identical or different and are C_8-C_{22} alkyl, alkenyl or alkynyl fatty acid radicals which are bonded by way of the carboxyl group;

Y = -NH-, -O- , -S-, or -OCO-;

R_3 is a covalently bonded polyethylene glycol (polyoxyethylene) -$(CH_2$-CH_2-$O)_n$-CH_2-CH_2-X,

where X = OR, $N[R]_2$, SR or COOR, and

R = H, benzyl-, or C_1-$_6$ alkyl, where, when X = $N[R]_2$, the [R] groups can be identical or different,

and wherein said bisacyloxypropylcysteine conjugate is a S-[2,3-bis(acyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol.